An oncolytic herpes simplex virus type 1 strain expressing a single-chain variable region antibody fragment against PD-1 and a PI3K inhibitor synergize to elicit antitumor immunity in ovarian cancer

[1]  G. Sonpavde,et al.  Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer , 2021, Journal for ImmunoTherapy of Cancer.

[2]  B. Kong,et al.  Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer , 2021, Journal of translational medicine.

[3]  F. F. de Melo,et al.  Oncolytic virus therapy in cancer: A current review , 2021, World journal of virology.

[4]  L. Morris,et al.  Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth , 2021, Frontiers in Immunology.

[5]  Wei Zhu,et al.  Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. , 2021, Cancer letters.

[6]  Sihan Chen,et al.  The Oncolytic Virus in Cancer Diagnosis and Treatment , 2020, Frontiers in Oncology.

[7]  N. Pavlidis,et al.  Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond , 2020, Drugs in R&D.

[8]  Xue F. Huang,et al.  An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses , 2020, Nature Communications.

[9]  N. Xia,et al.  Intratumoral Delivery of a PD-1–Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade , 2020, Cancer immunology research.

[10]  D. Yoon,et al.  Methyl lucidone induces apoptosis and G2/M phase arrest via the PI3K/Akt/NF-κB pathway in ovarian cancer cells , 2019, Pharmaceutical biology.

[11]  T. Chan,et al.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy , 2019, Nature Reviews Cancer.

[12]  G. Freeman,et al.  Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy , 2018, Clinical Cancer Research.

[13]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[14]  H. Kaufman,et al.  Integrating oncolytic viruses in combination cancer immunotherapy , 2018, Nature Reviews Immunology.

[15]  B. Vanderhyden,et al.  Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics , 2018, Cancers.

[16]  D. Bartlett,et al.  Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  M. Weller,et al.  Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models , 2018, Journal of Pharmacology and Experimental Therapeutics.

[18]  Imran M. Shaikh,et al.  Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma , 2018, Clinical Cancer Research.

[19]  S. Sajdak,et al.  Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer. , 2017, European journal of medicinal chemistry.

[20]  L. Boon,et al.  TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma , 2017, Molecular therapy oncolytics.

[21]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[22]  E. Bartee,et al.  Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. , 2017, Cancer research.

[23]  E. Chiocca,et al.  Oncolytic Viruses in Cancer Treatment: A Review , 2017, JAMA oncology.

[24]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[25]  S. Gottschalk,et al.  Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. , 2017, Cancer research.

[26]  Z. Guo,et al.  Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy , 2017, Nature Communications.

[27]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[28]  Thomas A. Sellers,et al.  Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.

[29]  Haiyan Zhang,et al.  Effects of celastrol on enhancing apoptosis of ovarian cancer cells via the downregulation of microRNA‑21 and the suppression of the PI3K/Akt‑NF‑κB signaling pathway in an in vitro model of ovarian carcinoma. , 2016, Molecular medicine reports.

[30]  Heidi Ledford.  Cancer-fighting viruses win approval , 2015, Nature.

[31]  C. von Kalle,et al.  CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[33]  Weiwei Zhu,et al.  PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. , 2014, Oncology reports.

[34]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[35]  H. Wakimoto,et al.  Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models , 2006, Gene Therapy.

[36]  E. Chiocca,et al.  Modification of HSV-1 to an oncolytic virus. , 2014, Methods in molecular biology.